Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Teva Pharmaceutical Industries : Says FDA Approves AirDuo Digihaler Inhalation Powder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/15/2019 | 09:19am EDT

By Michael Dabaie

Teva Pharmaceutical Industries Ltd. (TEVA) said the U.S. Food and Drug Administration approved AirDuo Digihaler Inhalation Powder.

That is a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application for information on inhaler use to people with asthma.

AirDuo Digihaler is indicated for the treatment of asthma in patients aged 12 and older.

The approval of AirDuo Digihaler is based on the review of the supplemental new drug application Teva submitted to the FDA.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
08/16TEVA 96 HOUR DEADLINE ALERT : Approximately 96 Hours Remain; Former Louisiana At..
BU
08/07Patient groups push back against Gilead's pricey HIV prevention treatment
RE
08/07ADR Shares End Higher; Teva Pharmaceutical, Commerzbank Trade Actively
DJ
08/07TEVA PHARMACEUTICAL INDUSTRIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCI..
AQ
08/07TEVA PHARMACEUTICAL INDUSTRIES : Seeks New CFO As It Faces High Debt Levels, Opi..
DJ
08/07TEVA PHARMACEUTICAL INDUSTRIES : Finance Chief Michael McClellan to Step Down
DJ
08/07TEVA PHARMACEUTICAL INDUSTRIES LTD : Change in Directors or Principal Officers (..
AQ
08/07TEVA PHARMACEUTICAL INDUSTRIES : Announces CFO Leadership Transition
BU
08/07TEVA PHARMACEUTICAL INDUSTRIES LTD : Results of Operations and Financial Conditi..
AQ
08/07TEVA PHARMACEUTICAL INDUSTRIES : Reports Second Quarter 2019 Financial Results
BU
More news
Financials (USD)
Sales 2019 17 165 M
EBIT 2019 4 023 M
Net income 2019 -62,8 M
Debt 2019 25 439 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
EV / Sales2019 1,60x
EV / Sales2020 1,45x
Capitalization 2 078 M
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 6,69  $
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-59.78%6 999
JOHNSON & JOHNSON2.48%346 681
ROCHE HOLDING LTD.12.24%238 299
MERCK AND COMPANY12.80%217 785
NOVARTIS17.81%204 677
PFIZER-19.40%191 651